Genprex (GNPX) announced the company has entered into a new Sponsored Research Agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that may predict patient response to Reqorsa Gene Therapy, the company’s lead drug candidate that is in development for the treatment of non-small cell lung cancer and small cell lung cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GNPX:
- Genprex announces presentations on Reqorsa Gene Therapy at 2026 AACR
- Genprex Highlights New Reqorsa Preclinical Data at AACR
- Genprex collaborators present on use of Reqorsa at AACR meeting
- Genprex Secures Key Global Patents for REQORSA Therapy
- Genprex granted Japanese and EU patents for Reqorsa Gene Therapy